NCT00330421 - Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

July 31, 2008

Conditions

Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic OsteosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent OsteosarcomaStage I Adult Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma

Interventions

DRUG

sorafenib tosylate

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo surgery

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

PROCEDURE

computed tomography

Correlative studies

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Correlative studies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH